Inhaled Pentamidine for Bolivian Mucosal Leishmaniasis

Jaime Soto Fundación Nacional de Dermatología, Santa Cruz, Bolivia;
Hospital Dermatológico de Jorochito, Santa Cruz, Bolivia;

Search for other papers by Jaime Soto in
Current site
Google Scholar
PubMed
Close
,
Patricia Gutiérrez Fundación Nacional de Dermatología, Santa Cruz, Bolivia;
Hospital Dermatológico de Jorochito, Santa Cruz, Bolivia;

Search for other papers by Patricia Gutiérrez in
Current site
Google Scholar
PubMed
Close
,
Paula Soto Fundación Nacional de Dermatología, Santa Cruz, Bolivia;

Search for other papers by Paula Soto in
Current site
Google Scholar
PubMed
Close
,
Julio Escobar ENT Service, Clínica Foianini, Santa Cruz, Bolivia;

Search for other papers by Julio Escobar in
Current site
Google Scholar
PubMed
Close
,
David Paz Hospital Dermatológico de Jorochito, Santa Cruz, Bolivia;

Search for other papers by David Paz in
Current site
Google Scholar
PubMed
Close
,
Daniela Rivero Hospital Dermatológico de Jorochito, Santa Cruz, Bolivia;

Search for other papers by Daniela Rivero in
Current site
Google Scholar
PubMed
Close
,
Aracely Villalba Hospital Dermatológico de Jorochito, Santa Cruz, Bolivia;

Search for other papers by Aracely Villalba in
Current site
Google Scholar
PubMed
Close
, and
Jonathan Berman AB Foundation, North Bethesda, Maryland;
Fast-Track Drugs, Potomac, Maryland

Search for other papers by Jonathan Berman in
Current site
Google Scholar
PubMed
Close
Restricted access

Aerosolized pentamidine is Food and Drug Administration approved to treat Pneumocystis pneumonia via a route that does not lead to systemic absorption or toxicity. Because Leishmania is also susceptible to pentamidine and mucosal leishmaniasis is also an infection of the respiratory tract, we performed a pilot study of aerosolized pentamidine (300 mg for 10 days over approximately 4 weeks) for mucosal leishmaniasis caused by Bolivian Leishmania braziliensis with a 2-year follow-up. Of 15 patients, 6 of 7 patients with initially mild disease were cured, 3 of 4 patients with initially moderate disease relapsed at the 18- to 24-month follow-up visits, and 3 of 4 patients with initially severe disease failed early after treatment. This study suggests that inhaled pentamidine may be useful as a well-tolerated treatment of mild mucosal leishmaniasis and that to rule out relapse, mucosal leishmaniasis follow-up should extend to 2 years.

Author Notes

Financial support: This work was supported by a grant from the AB Foundation to J. Soto.

Disclosures: J. Berman is an officer of the AB Foundation, the granting agency for this work. The protocol was approved by the Comite de Bioetica de la Facultad de Medicina, Universidad Mayor de San Simon, Cochabamba, Bolivia.

Current contact information: Jaime Soto and Patricia Gutiérrez, Fundación Nacional de Dermatología y Hospital Dermatológico de Jorochito, Santa Cruz, Bolivia, E-mails: jaime.soto@infoleis.com and pgutierrezduenas@gmail.com. Paula Soto, Fundación Nacional Dermatología, Santa Cruz, Bolivia, E-mail: dra.paula.dermalaser@gmail.com. Julio Escobar, ENT Service, Clínica Foianini, Santa Cruz, Bolivia. David Paz, Daniela Rivero, and Aracely Villalba, Hospital Dermatológico de Jorochito, Santa Cruz, Bolivia, E-mails: davidpazmendoza@hotmail.com, p_d_rivero@hotmail.com, and chelycita83@gmail.com. Jonathan Berman, AB Foundation, North Bethesda, MD, E-mail: jberman@fasttrackresearch.com.

Address correspondence to Jaime Soto, Torre Link, Piso 2. Cuarto Anillo entre Roca Coronado y Radial 21, Santa Cruz de la Sierra, SC, Bolivia. E-mail: jasm.dlb@gmail.com
Past two years Past Year Past 30 Days
Abstract Views 232 232 232
Full Text Views 9 9 9
PDF Downloads 9 9 9
 

 

 

 
 
Affiliate Membership Banner
 
 
Research for Health Information Banner
 
 
CLOCKSS
 
 
 
Society Publishers Coalition Banner
Save